Clinical Applications

Nuclear Medicine / Radiology

A targeted radiotracer, with the potential to enable PET to detect tumor with greater precision.


Nuclear Medicine
Nuclear Medicine

These are two PET-CT scans of the same melanoma-laden subject. The image on the left uses 18F-FDG, a current standard of care. The image on the right uses 124I-cRGDY-PEG-C-Dots. The authors noted the improved ability of C-Dots in discriminating cancer from inflammatory tissue.

M. S. Bradbury, E. Phillips, P. Montero Miranda, S. M. Cheala, H. Stambuk, J. C. Durack, C. T. Sofocleous, R. J. C. Meester, U. Wiesner, S. Patel, Clinically-Translated Silica Nanoparticles as Dual-Modality Cancer-Targeted Probes for Image-Guided Surgery and Interventions, Integr. Biol. 5 (2013), 74-86. Figure 8.

Surgical Oncology

A cancer-targeting diagnostic probe with a fluorescent core.


Surgical
Existing products cannot provide visual identification of cancer.
Surgical
Currently in human clinical trials, C-Dots are designed to enable the surgeon to see cancer, in real-time, during surgery.

C-Dots are showing the potential to enable surgeons to see cancer, in real-time during surgery to facilitate identification and removal of tumor and tumor-bearing lymph nodes. This product candidate is currently in clinical trials for sentinel lymph node mapping, a procedure used to determine if cancer has spread to the lymph nodes.

As the first image shows, current products, including the standard of care, don't selectively identify cancer or provide any visual confirmation to the surgeon during the procedure. The second image shows our first product candidate, cRGDY-PEG-C-Dots, being used in combination with a commercially available near-infrared camera system. Our product candidate is designed to allow the surgeon to see cancer, in real time, during this sentinel lymph node mapping surgery, to enable greater precision and real-time decision making.

Medical Oncology

A targeted Nanoparticle Drug Conjugate™ with Target or Clear™ capabilities, designed to improve efficacy and reduce side effects.

These NDC™ C-Dots are designed to carry drug, to target and penetrate cancer cells and to release the drug upon exposure to enzymes inside given cancer cells. Approximately 95% of remaining NDC C-Dots are expected to safely clear from the body through the kidneys.

Barney Yoo, Kai Ma, Li Zhang, Andrew Burns, Sonia Sequeira, Ingo Mellinghoff, Cameron Brennan, Ulrich Wiesner and Michelle S. Bradbury. Ultrasmall Dual-Modality Silica Nanoparticle Drug Conjugates: Design, Synthesis, and Characterization. Bioorg Med Chem. 2015 November 15; 23(22): 7119-7130

Radiation Oncology

A targeted radiotherapeutic with the potential to offer enhanced outcomes alone or in combination with immunotherapy.

C-Dots have the potential to combine accurate cancer cell targeting with a radiotherapeutic payload. We are investigating whether such nanoparticle radiotherapeutic conjugates can provide a more accurate radiotherapy treatment with the particle penetrating and irradiating the tumor, enhancing cell kill.